ASCO and College of American Pathologists Issue Guideline for HER2 Testing

作者
&NA;
出处
期刊:Oncology times [Wolters Kluwer]
卷期号:35 (21): 41-42
标识
DOI:10.1097/01.cot.0000437972.11009.e4
摘要

FigureThe American Society of Clinical Oncology and the College of American Pathologists have issued a joint, updated guideline for human epidermal growth factor receptor 2 (HER2) testing in patients with breast cancer, designed to improve the accuracy of such testing and its utility as a predictive marker in invasive breast cancer. The guideline, published online ahead of print in the Journal of Clinical Oncology (doi: 10.1200/JCO.2013.50.9984 ), updates the original 2007 ASCO/CAP guideline recommendation for HER2 testing and is based on a systematic review of the literature and provides detailed recommendations for how to test for HER2 overexpression, interpret the results, and recommend HER2-targeted therapies. The joint guideline was prepared by an ASCO/CAP Update Committee of experts in breast cancer and cancer biomarkers. “Improvements in testing performance and a better understanding of HER2 biology allowed the panel to tackle less common clinical scenarios, and give clinicians and patients the best possible information to individualize clinical decision-making, and ensure the right treatment is offered to the right patient,” said Antonio C. Wolff, MD, FACP, Co-chair of the ASCO/CAP HER2 Testing in Breast Cancer Panel and Professor of Oncology at Johns Hopkins Kimmel Comprehensive Cancer Center. HER2-targeted therapies, such as trastuzumab, lapatinib, pertuzumab, and T-DM1, are known to substantially increase survival in patients with HER2-positive invasive breast cancer. Accurate identification of HER2 status ensures that patients most likely to benefit are offered HER2-targeted treatments, and also that those unlikely to benefit can avoid the side effects and costs associated with those drugs. “Six years ago, our main concern was the unacceptably high number of false-positive test results observed in the first generation of adjuvant trastuzumab trials,” explained M. Elizabeth Hammond, MD, the other Co-chair of the Panel and Professor of Pathology at the University of Utah School of Medicine. “As a direct result of the 2007 guideline, there has been greater standardization of tissue handling procedures, improvements in laboratory performance of HER2 testing, and the development of more clear reporting criteria for test results. These improvements allowed the panel to update international standards to further improve the accuracy of HER2 testing, and allow all appropriate patients to be considered for HER2-targeted therapies.” The updated guideline also adds recommendations for the newer diagnostic technique of bright-field in-situ hybridization (ISH), in addition to immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH), both of which were included in the original guideline. The key recommendations from the guideline are: Always test HER2 status on all newly diagnosed invasive breast cancers (primary site and/or metastatic site)—and ensure that at least one tumor sample is tested for either HER2 protein expression (IHC or ISH assay) for HER2 gene amplification. Discuss the role of HER2-targeted therapy if the HER2 test result is positive and if there is no apparent histopathologic discordance with HER2 testing. Delay the decision to recommend HER2-targeted therapy if the HER2 test result is equivocal. Mandatory retesting should be done on the same specimen using the alternative test if the initial HER2 test result is equivocal or on an alternative specimen. Do not administer HER2-targeted therapy if the HER2 test result is negative. If there is apparent histopathologic discordance with the HER2 test result, additional HER2 testing should be considered. Report a HER2 test result as indeterminate if technical issues prevent one or both tests (IHC and ISH) from being done in a tumor specimen, or prevent the test (or tests) from being reported as positive, negative, or equivocal. Confirm that the testing laboratory conforms to standards set for accreditation by CAP or an equivalent accreditation authority. In rare cases, it may be difficult to know for sure if the result is positive or negative. If additional testing on other tissue specimens is not possible, pathologists and oncologists should consider all available clinical data on the patient prior to recommending HER2-targeted therapy. More detailed recommendations specifically for oncologists and for pathologists are listed in the guideline. The updated guideline also emphasizes the critical need for collaboration by all health care providers and organizations involved in the diagnosis and treatment of breast cancer patients, Wolff said via email. “This may turn out to be as simple as picking up the phone, or sending a quick email to discuss a case where a test result may appear to be discordant with clinical scenarios or other standard pathology measures.” And, the guideline indicates key points for clinicians to discuss with patients regarding HER2 status and includes these recommendations for patient and clinician communication on the topic: Explain the importance of determining the biologic characteristics of breast cancer; Explain the type of tissue used for HER2 testing; Explain the types of test used to determine HER2 status; Explain the interpretation of the HER2 test results; Explain the importance of—when appropriate—retesting HER2 status in new, metastatic tumors; and Explain that HER2 testing guidelines exist. The guideline, as well as a companion guide, additional clinical tools, and an infographic for patients are available at ASCO.org.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
精明依云发布了新的文献求助10
刚刚
2秒前
2秒前
顾矜的应助被zy采纳,获得10
2秒前
2秒前
哭泣的访文完成签到,获得积分10
3秒前
秋风的应助被玩命做科研采纳,获得10
3秒前
千秋凌发布了新的文献求助20
3秒前
3秒前
漫漫发布了新的文献求助10
3秒前
rui发布了新的文献求助10
4秒前
潇洒的钥匙完成签到,获得积分10
4秒前
5秒前
Fun_112发布了新的文献求助30
5秒前
5秒前
上官若男的应助被oooaaa采纳,获得10
5秒前
banana发布了新的文献求助10
5秒前
今后的应助被oooaaa采纳,获得10
5秒前
好果汁完成签到,获得积分20
5秒前
清辉影的应助被oooaaa采纳,获得30
5秒前
NexusExplorer的应助被刘厚麟采纳,获得10
5秒前
小蘑菇的应助被oooaaa采纳,获得10
5秒前
北月南弦完成签到 ,获得积分10
7秒前
7秒前
zhouleiwang完成签到,获得积分10
7秒前
好果汁发布了新的文献求助10
7秒前
斯文败类的应助被专一的弱采纳,获得10
7秒前
JIN完成签到,获得积分10
7秒前
starcraftfan发布了新的文献求助10
8秒前
ICE发布了新的文献求助10
8秒前
思源的应助被木木采纳,获得30
9秒前
等风归发布了新的文献求助10
9秒前
9秒前
9秒前
芝麻发布了新的文献求助10
10秒前
科研通AI6.3的应助被yoyo122采纳,获得10
10秒前
华仔的应助被醉熏的寄松采纳,获得10
10秒前
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621